"Quantum BioPharma is preparing to enter phase 2 clinical trials for Lucid-MS, a drug candidate for multiple sclerosis. The drug targets the myelin sheath directly, distinguishing it from existing immune-modulating therapies. The company submitted an IND application to the FDA in April 2026."